GSK today news: R&D setback weighs, but price steadies in tight $1,643

Traders Union
All News
Financial News
GSK slips 0.36% today despite strength

Highlights

GSK plc traded at $1,646.50, maintaining momentum above the 20-day ($1,618.45), 50-day ($1,530.50), and 200-day ($1,451.01) moving averages.
On October 22, 2025, GSK repurchased 248,000 shares at $1,644.38 each, contributing to over 5.3 million shares bought back since September 30, 2025.
Technical analysis signals an 80%+ probability of further gains, with the price consolidating between $1,643.00–$1,651.00 and risk only if below $1,640.

Buyback activity and investor accumulation offset by R&D pipeline risks

GSK repurchased 248,000 shares at an average price of $1,644.38 on October 22, 2025 as part of its ongoing buyback program, with more than 5.3 million shares bought back since September 30, 2025 to return capital to shareholders. Institutional investors, including Cullen Frost Bankers Inc. and Ethic Inc., increased holdings following the company's quarterly earnings beat with an EPS of $1.23 and revenue of $10.64 billion, up 1.3% year-over-year. Additionally, recent R&D setbacks in dementia drug partnership with Alector have raised some concerns about GSK’s brain drug pipeline.

Mixed momentum with resistance at $1,650 amid low volatility range

The technical outlook for GSK remains positive, with prices trading above all major moving averages. The nearest dynamic support lies at the Ichimoku Kijun of $1,569.75, while resistance is seen near the recent high and the psychological $1,650 mark. Momentum signals are mixed — the daily MACD is bullish and RSI at 56.08 indicates mild upward bias, but a high ADX (40.78) flags possible trend exhaustion. Other oscillators such as CCI (73.35) and Stoch RSI suggest mild bullishness, with volatility remaining low as the price consolidates in the $1,643.00–$1,651.00 daily range.

Upside favored as technicals reinforce post-range breakout potential

Over the next five trading days, GSK is expected to fluctuate between $1,640.50 and $1,653.73 with an average near $1,647.12. Technicals signal a more than 80% probability of continued gains, supported by strong buy signals from weekly RSI, MACD, and moving averages. The baseline scenario is range-trading just above $1,640, with bullish extension likely if the price breaks above $1,651. Downside risk would be triggered only if GSK falls and holds below the $1,640 level.

Anton Kharitonov, expert at Traders Union, sees GSK’s sustained technical strength above key moving averages as a constructive sign, but remains cautious due to mixed momentum signals and ongoing concerns about R&D setbacks in its brain drug pipeline. He notes that while institutional accumulation and a recent earnings beat support the stock fundamentally, high ADX readings and muted volatility suggest the current uptrend may be losing steam. 'The base case is for GSK to range just above $1,640, with a bullish extension possible only if $1,651 is broken — until then, I remain defensive given downside risks if $1,640 fails to hold.'

Source of Data: GSK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.